RAS effectors specifically interact with the GTP-bound form of RAS in response to extracellular signals and link them to downstream signaling pathways. The molecular nature of effector interaction by RAS is well-studied but yet still incompletely understood in a comprehensive and systematic way. Here, structure-function relationships in the interaction between different RAS proteins and various effectors were investigated in detail by combining our in vitro data with in silico data. Equilibrium dissociation constants were determined for the binding of HRAS, KRAS, NRAS, RRAS1 and RRAS2 to both the RAS binding (RB) domain of CRAF and PI3Kα, and the RAS association (RA) domain of RASSF5, RALGDS and PLCε, respectively, using fluorescence polarization. An interaction matrix, constructed on the basis of available crystal structures, allowed identification of hotspots as critical determinants for RAS-effector interaction. New insights provided by this study are the dissection of the identified hotspots in five distinct regions (R1 to R5) in spite of high sequence variability not only between, but also within, RB/RA domain-containing effectors proteins. Finally, we propose that intermolecular β-sheet interaction in R1 is a central recognition region while R3 may determine specific contacts of RAS versus RRAS isoforms with effectors.
Introduction
RAS family proteins, including HRAS, KRAS, NRAS, RRAS1, RRAS2 (or TC21), RRAS3 (or MRAS) and ERAS, act as signaling nodes and regulate the function of various effectors with divergent biochemical functions in all eukaryotes [1, 2, 3] . Signal transduction implies physical association of these proteins with a spectrum of functionally diverse downstream effectors, e.g., CRAF, PI3Kα, RALGDS, PLCε and RASSF5, and their activation [1, 4, 5, 6, 7, 8, 9, 10] . CRAF, a serine/threonine kinase, activates the MEK-ERK axis and controls gene expression and cell proliferation [11] . PI3Kα generates phosphatidylinositol (3, 4, 5) -trisphosphate (PIP 3 ) and regulates cell growth, cell survival, cytoskeleton reorganization, and metabolism [12] . RALGDS links RAS with RAL, a RAS-related protein, and regulates cellular processes, such as vesicular trafficking and migration [13] . PLCε generates two second messengers of diacylglycerol (DAG) and inositol trisphosphate (IP 3 ) leading to an intracellular increase of calcium levels, using fluorescence polarization. In addition, available complex structures and sequence alignments were utilized to construct an interaction matrix and systematically assess the association of investigated effector domains with various RAS proteins. The dissociation constants (K d values) obtained were combined with the interaction matrix enabling us to determine common hotspots as critical specificity-determining residues and to predict selectivity of five RB-and RA-containing proteins.
Materials and Methods Constructs
Fragments of human genes encoding both RBs of CRAF (accession number P04049; amino acids or aa 51-131), PI3Kα (P42336; aa 169-301), and RAs of RALGDS (Q12967; aa 777-872), PLCε (Q9P212; aa 2130-2240), RASSF5 (Q8WWW0; aa 200-358) were cloned into pMalc5X-His vector. Constructs for the expression of human HRAS, KRAS, NRAS, RRAS1 and RRAS2 isoforms were described previously [5] .
Proteins
All RAS and the effector proteins were expressed in Escherichia coli using the pGEX and pMAL-His expression systems and prepared using glutathione and Ni-NTA based affinity chromatography as described previously [18] . RAS-mGppNHp was prepared as described [18] .
Fluorescence polarization RAS-effector interaction was performed in 50 mM Tris/HCl pH 7.5, 100 mM NaCl, 5 mM MgCl 2 and 3 mM dithiothreitol at 25˚C using a Fluoromax 4 fluorimeter in polarization mode as described [18] . Increasing amounts of MBP-tagged effector proteins (0.05-100 μM) titrated to 1 μM RAS-mGppNHp resulted in an increase of polarization. Equilibrium dissociation constants (K d ) were calculated by fitting the concentration dependent binding curve using a quadratic ligand binding equation.
Sequence and structural analysis
Sequence alignments were performed with Bioedit program using the ClustalW algorithm [44] . Chimera was used to adjust sequence alignments with superimposed structures [45] . A python code was written to match sequence alignments with complex structures (S1 Table) and calculate intermolecular contacts in the form of an interaction matrix. The intermolecular contacts were defined as pairs residues with a distance 4.0 Å between effectors and RAS proteins in available complex structures in the protein data bank (http://www.pdb.org). Biopython modules [46] were also used to elucidate corresponding residues in all available complex structures. All structural representations were generated using PyMol viewer [47] .
Results

A general approach for quantitative study of RAS-effector interaction
As previous studies focused mainly on HRAS interaction with effectors, there is a lack of information for other RAS proteins (Table 1) . Dissociation constants (K d values) have been invaluable in providing insights into particular RAS-effector interactions. However, they have been obtained under various conditions using diverse experimental techniques (see Table 1 ) and cannot be used as such for a comparative evaluation of the interaction of different RAS proteins with various effectors. For this reason, we set out to analyze the interaction of HRAS, KRAS, NRAS, RRAS1 and RRAS2, with five distinct RB-and RA-containing effectors (Fig 1) under the same conditions. Since the kinetic analysis using stopped-flow spectrofluorometric method was not applicable to all isolated effector proteins, we utilized the fluorescence polarization approach [48] . Therefore, we prepared both, the RAS proteins in complex with mant (m) GppNHp, a nonhydrolysable fluorescent GTP analog, and the effector proteins fused to maltose-binding protein (MBP, 42 kDa). We chose the MBP because it increases the molecular mass of smallsized RB or RA domains, leads to an amplified fluorescence signal (Fig 2A) and ensures a homogeneous monomeric form of the fusion proteins. GST-fusion protein in contrast yielded a mixture of dimeric and monomeric species (data not shown). Equilibrium titration experiments revealed sufficient signal changes upon binding and guaranteed comparable experimental conditions for all measurements. By taking advantages of this method, complexes formed between these two types of proteins provided distinct polarized signals (Fig 2A and S1 Fig) that enabled us to determine K d values for RAS-effector interactions ( Table 2) .
The affinities determined for the interaction between RAS proteins and individual effector domains vary between 48 nM for the NRAS-CRAF interaction and 205 μM for the interaction between KRAS and PI3Kα ( Fig 2B; Table 2 ). In general, the tested RAS proteins can be nicely divided according to their affinities into two distinctive groups, the first comprising HRAS, KRAS, NRAS and the second the RRAS proteins. Highest affinities were obtained for CRAF, which were roughly 3-8 fold higher when compared to those for RASSF5, followed by RALGDS and PLCε with K d values in the lower micromolar ranges (Fig 2B; Table 2 ). In contrast, RRAS1 and RRAS2 have similar micromolar affinities for the effectors and, interestingly, also for PI3Kα but not for PLCε. Our data clearly support previous findings (see Table 1 ) that isolated effector domains, such as RB or RA, represent functional units, capable of recognizing and tightly binding to RAS proteins. Exceptions are the low affinity of PLCε RA domain for the RRAS proteins and PI3Kα RB domain for HRAS, KRAS and NRAS.
Identification of hotspots within protein interfaces
To date eleven complex structures of RAS proteins and their effectors has been determined (S1 Table) . Since some of them contain more than one complex in the unit cell, there were altogether sixteen complex structures available for the analysis. In order to map atomic interactions responsible for observed variable affinities, we have extracted information about interacting interface from all these complex structures and combined them with their sequence alignments (S2 and S3 Figs). Interestingly, effectors show low sequence similarity (S2A Fig) , but their mode of interaction appears to be well conserved as can be seen after a superposition of the complex structures on the RAS structure (Fig 3 and S4 Fig) . However, some amino acids aligned according to the sequence were quite distant in the space. Therefore, we edited the sequence alignment to synchronize it with structural alignment (S2A Fig). Our python code finally took sequence alignments with PDB files of complex structures as inputs and calculated all interaction pairs in analyzed complex structures in the form of a matrix (Fig 4A) .
Interaction matrix and binding regions
An interaction matrix relates, in a comprehensive manner, the interacting residues on both sides of complexes, with RAS isoforms as rows and effector proteins as columns ( Fig 4A) . All numbering in this study is based on HRAS and CRAF proteins. Each element of the matrix accounts for the number of contacts between corresponding residues in all analyzed structures. Residues, involved in at least one interaction, were considered to represent a general interaction interface between RAS proteins and their effectors. Interacting amino acids form continuous patches on both sides of the complexes. Particular modes of interactions between parts of these two patches correspond to regions in the interacting matrix. We identified five such distinct regions (denoted from R1 to R5) in the matrix which had the highest number of interactions. These are separately highlighted in Fig 4. Most pronounced is R1, located in the middle of matrix. Inspection of the particular interactions corresponding to this region clearly shows an arrangement of intermolecular β-sheet interactions in an anti-parallel fashion ( Fig 4B) . As many of these contacts in R1 are mediated by main-chain/main-chain interactions, we divided each element of R1 in the matrix into four categories of interactions (main-chain-main-chain, main-chain-side-chain, side-chain-mainchain and side-chain-side-chain; S5 Fig) . Main-chain-main-chain interactions typically involve hydrogen bonds between the N-H group and the carbonyl oxygen. We found three interaction hotspots in all RAS-effector complexes, which represent a central recognition site in R1. These amino acids are Glu-37, Asp-38 and Ser-39 from the RAS side and positions 66 to 69 from the effector side ( Fig 4A, red box) . However, side-chain interactions are also highly Another distinct region is R2, which corresponds to the interactions between the residues 21 to 34 of RAS, including the N-terminal half of switch I, and an elongated loop containing an α helix (in the case of PLCε and PI3Kα) and two α helices covering positions 83 to 90 (Fig  4) . However, the overall shape of corresponding amino acids as well as the spatial orientation of α-helical structures is very diverse (Fig 4B) . These structural diversities not only cause widely dispersed interactions in R2, but are also responsible for the interactions in the frames of region R4. The capability of RB domains in R2 to interact also with the β-strand in switch I of RAS simultaneously involves the recognition region R1 and gives rise to the region R4 ( Fig  4B; upper panel) . On the other hand, the spatial position of the N-terminal residues of RA domains in R1 is similar to the position of the C-terminal residues RB domains in R2 resulting in the interactions established in the region R5. Remarkably, the interaction matrix gives the hints for a region R3 (Fig 4) that could not be defined as a general interaction patch from a direct pair-wise comparison of individual complex structures. This region comprises critical residues, including Ile-36, Glu-37 and Tyr-64 on the RAS side, and positions 57, 59 and 71 on effector side. R3 very likely determines the selectivity of RAS-effector interaction, especially because of sequence deviations at this region (Arg-41 and Tyr-64) when comparing HRAS, KRAS and NRAS with RRAS1, RRAS2, RRAS3. Strikingly, the binding affinities between these two groups of RAS subfamilies are indeed different.
Discussion
Since the discovery of the first RAS effector [49,50,51,52], inhibition of RAS signaling by blocking RAS-effector interactions has been an ever-evolving and challenging venture [53, 54, 55, 56] . Biochemical and biophysical studies providing insights into the interaction of the downstream effectors with RAS proteins and their variants established the basic principles for drug design and development [31,43,53,57,58]. There is, however, a quite significant gap in our understanding of how RAS proteins specifically bind to, and activate, their diverse effectors. Rigorous understanding of this RAS-effector interplay would require an investigation of larger fragments or full-length effector proteins that was so far been accomplished in only a few studies [36, 59, 60] . For several reasons, isolated effector domains have been used in the vast majority of biochemical and structural studies for the investigation of their interactions with RAS proteins, predominantly with HRAS (Table 1 and S1 Table) . However, interaction characteristics obtained for the same proteins differ considerably. For example, K d values for the interaction of HRAS-GTP with CRAF or RALGDS vary from 5 to 330 nM and 80 nM to 39 μM, respectively (Table 1 ). Another major difference of more than two orders of magnitude was observed for the interaction between RRAS1 and CRAF. Such a large variation of K d values (summarized in Table 1 ), which in addition have been determined by different groups using different methods and experimental conditions, made a comprehensive analysis of sequence-structure-function relationships practically impossible. Thus, we have quantitatively analyzed the interaction between five effector domains and five RAS proteins, covering for the first time RRAS2, under the same conditions (Table 2) .
Our measurements reveal that the RAS isoforms (HRAS, KRAS and NRAS) behave similarly toward each effector but very differently as compared to RRAS isoforms (RRAS1 and RRAS2), in spite of their high sequence identity. A previous study has reported that RAS isoforms much more strongly activate the MAPK pathway via the RAF kinase as compared to RRAS isoforms [60] . These data are consistent with K d values determined in this study for RAS (ranging 0.048 to 0.142 μM) and RRAS (2.29 to 4.09 μM) isoforms. Notably, RRAS isoforms bind, except for PLCε, similarly to all tested effector domains with an up to 4-fold difference in binding affinities compare to RAS isoforms. Interestingly, they significantly interacted with PI3Kα but not with PLCε (Table 2) , which is in agreement with the cell-based data reported previously [60] .
In particular, the RAS isoforms, which exhibit high selectivity for CRAF followed by RASSF5, RALGDS and PLCε, appeared not to retain affinity for PI3Kα. It could be argued that the isolated RB domain of PI3Kα (consisting of the amino acids 169-301) may lack additional binding determinants, when compared to the 50-fold higher affinity obtained with the isolated RB domain of PI3Kγ (amino acids 144-1102) (Tables 1 and 2) [36] . A recent cellbased study has shown that RB domain of PI3Kα (aa 127-314) is sufficient to bind to ERAS, a newly discovered member of the RAS family, but obviously not to HRAS [5, 61] . However, the immunoprecipitation studies have revealed the endogenous PI3K isoforms α and γ interact with almost same affinity with both ERAS and HRAS [5] . These data suggest that RB domain of PI3K is sufficient for a tight interaction with ERAS but clearly requires additional capacity to properly associate with HRAS. Sequence deviations in effector binding regions may be critical for determining the minimal binding regions of RAS/effectors. It is, therefore, hypothesized that ERAS and RRAS isoforms but not RAS isoforms efficiently interact with RB domain of PI3Ks and that RAS isoforms need a second binding region or alternatively a scaffold protein.
Considering the affinities of RAS isoforms compared to RRAS isoforms, these are very similar for both groups regardless of the effector protein. Correspondingly, the RAS isoforms have identical effector binding regions and RRAS isoforms, also including RRAS3, revealed a very high sequence identity in these regions (S3 Fig). Considering differences in affinities between them, residues outside the interacting interface may play a role in the association via indirect long-range interactions, electrostatic steering or allosteric modulation. However, direct interacting residues that differ between these two classes of proteins are most likely to be responsible for observed differences. Noteworthy, there are only two such amino acids in the region R3 with significant occurrence in the interaction at position 41 (Arg/Thr in RAS isoforms compared to RRAS isoforms) and 64 (Tyr/Phe). R41 in RAS isoforms interacts favorably with asparagine and aspartic acid in CRAF respectively RASSF5, most likely stabilizing the high affinity interactions with the effector proteins. These interactions appear to be much weaker if Arg-41 is replaced by a threonine in RRAS isoforms. This explains, thus, huge differences in K d between the RAS isoforms and the RRAS isoforms. The same arginine does not make such favorable contact with RALGDS or PLCε, contributing to lower affinities. Its interaction with counter residues in PI3K is loose in all analyzed complexes corresponding to higher K d values for this effector. Interaction at this spot may determine effector selectivity between these isoforms, as confirmed for ERAS that has a tryptophan (Trp-79) at the corresponding position of Arg-41 in HRAS and has exhibited a higher selectivity for PI3K than CRAF [61] . Another crucial hotspot at position 64 of the RAS proteins very likely also plays an important role in the interaction with effectors. In accordance with the interaction matrix, it is in the vicinity of residues at effector positions 57 and 71, respectively. The mode of interaction between these residues, however, is not pronounced as in the case of Arg-41. Substitution of Tyr-64 for Phenylalanine may have very diverse impacts on the binding affinity.
The RB and RA domains share higher sequence homologies if they are aligned individually. However, there is no common consensus sequence for RAS binding if they are aligned together, particularly in the RAS binding regions R1 to R5 ( S2 Fig; see arrowheads) . Previous studies dealing with the interaction of small GTPases with their regulators have shown that there are patches of identical or highly homologous hotspots on both sides of protein surfaces that interact with each other [62,63,64]. Such interaction is evolutionary conserved and responsible for the recognition of counter proteins. Our finding that there is no patch of identical amino acids in RAS effector proteins (Fig 4 and S2 Fig) seemed to break this rule. However, intermolecular β-sheet interactions between RAS proteins and their effectors are conserved and seem to supply the role of such critical patch (or in this special case, a stretch) of homologous amino acid residues. The analysis of complex structures showed that these interactions, covered by the recognition region R1 in the interaction matrix, are prevalent and occur in almost all structures. A β-sheet homodimer interface has been recently reported for the structures of KRAS-GTP that overlaps the binding site of the effectors within R1 [65] . Therefore, we have analyzed the proximity of effector binding residues in different RAS isoforms in the same way as of residues involved in β-sheet interactions and summarized the results as matrices (Fig 4A and S5 Fig) . Introduction of four different interaction types in the matrix with high scores that separated main-chain and side-chain RAS-effector interactions allowed a detailed inspection of the central R1 region. Strikingly, there are three hotspots, which largely undergo main-chain/main-chain interactions (Glu-37 of RAS proteins with effector residues at position 68 and 69, respectively Asp-38 with residues at position 67; S5  Fig) . These observations confirm the central role of R1 in the association of RAS proteins with their effectors and strongly suggest that the main-chain/main-chain interactions within this region are crucial for the recognition of these classes of proteins. Finally, we note that interactions in R1 also dependent, to a certain extent, on side chains of accompanying amino acids. They indirectly support the formation of β-sheet on both sides of complexes. However, they also utilize their side chains in another intramolecular interactions significantly contributing to the complex formation. In this way, Asp-38 interacts via its side chain exclusively with the effector residues at positions 68 and 69 within R1. Side chains of Glu-37 and Ile-37 undergo contacts with residues at positions 57 and 59 outside of the effector β-strand within the region R3. On the effector side of complexes, there are only two positions that contain identical or highly homologous amino acids, namely the position 59 and 84 (Fig 4A) . In both cases they are populated by positively charged residues, with exception of PLCε that has a Gln at position 59. These residues interact with negatively charged residues on RAS proteins (Glu-37 and Asp-33) and strongly contribute to the formation of complexes. However, no unique and/or particular residue of effectors can be considered to cause the overall differences observed for their association with RAS proteins. Effector interacting residues are so variable at almost all interacting spots that only their concerted action is likely to explain the observed diversity.
Previous studies have shown that RAS variants (at residues Thr-35, Glu-37, Asp-38 and Tyr-40 and including also residues mentioned above) preferentially interact with some effectors but not others [39, 40, 41, 42] . However, to date there is no clear explanation for the variable selections of these mutants of RAS by specific effectors. The invariant Thr-35 of RAS was not located in one of the three main regions in the matrix as it is mainly involved in RAS structure and does not directly interact with RAF1. However, Spoerner and colleagues have shown that T35S mutation drastically reduces HRAS affinity for effectors, including CRAF-RB (60-fold) and RALGDS-RA (>100-fold) [66] . They suggest that minor changes, such as truncating Thr-35 by a methyl group, strongly affect dynamic behavior of the switch 1 region and, in turn, its interaction with effectors. However, an early cell-based study has shown that HRAS T35S mutant interacts only with CRAF but not PI3K, BYR2, RALGDS or RASSF5, and activates the MAPK pathway [39] . One explanation may be that Gal1 scaffolds the HRAS T35S -CRAF [67] . On the other hand, the E37G mutation results in loss of PI3K and CRAF binding, but is able to interact with RA domain-containing effectors, such as RALGDS, RASSF5 and BYR2 [39] . Our interaction matrix shows contacts between E37G of HRAS and positively charged residues 61 and 69, and main-chain interactions with residue 69, and 70 of effectors. D38A mutation has been shown to retain CRAF binding but to lose interaction with PI3K, RALGDS and RASSF5 [42, 68] R4, our analysis not only confirms a prominent role of Glu-37, Asp-38 and Tyr-40 in effector binding but also gives hints for the mode of their interaction, which relies on the main-chainmain-chain interaction. As this interaction is largely independent of associated side chains, it can be considered as conserved in effectors. Consequently, it supplies the role of homologous residues found to be essential for the recognition of regulator proteins by Rho GTPases. Hence, we state that these RAS residues are responsible with their main-chain atoms for the recognition of effectors. On the other hand, side chains of these residues are still influential on the binding with effectors, either indirectly by affecting the structure of RAS switch I or directly by interacting with effector residues within the regions R3 and R4 of our interaction matrix.
In conclusion, our data collectively support previous observations that the specificity in the signaling properties and biological functions of the various RAS proteins arises from the specific combination of effector pathways they regulate in each cell type. Considering the identity of interacting residues of different types of isoforms, a uniform association of RAS isoforms or rather RRAS isoforms can be expected with a particular effector. This raises the questions of how does the cell selects between respective RAS proteins and maintains respective effector activation. There are several review articles illustrating the current state of the art regarding the activation mechanism of various effectors [9, 11, 12, 13, 21, 71, 72, 73] . HRAS, KRAS and NRAS exhibit remarkable differences beyond their common interaction interfaces for regulators and effectors [74, 75, 76] , especially at their C-terminal hypervariable region (S3 Fig), which has different features, including protein-protein interaction [77, 78] . An interesting issue, which is increasingly appreciated, is a RAS-membrane interaction that appears to generate RAS isoform specificity with respect to effector interactions [79, 80, 81] . This is likely achieved by RAS-specific scaffold proteins, including CaM, GAL1, GAL3, IQGAPs, NPM1, NCL, SHOC2/SUR8 [78, 82] , which may modulate isoform specificity at specific site of the cell. Hence, elucidation of the RAS signal transduction requires not only RAS-effector interactions but also additional structures and interplay of multiprotein complexes [25] . Another critical aspect is sorting/trafficking of the isoforms [83, 84] that has recently been shown to be highly specific for the respective RAS proteins and dependents on specific posttranslational modifications, including prenylation and acylation [85, 86] [101] . The N-terminus of ERAS, which undergoes multiple interaction with other proteins (Nakhaeizadeh et al., unpublished), contains (like RRAS1) putative SH3-binding motifs. These motifs may provide additional mechanisms for sorting and trafficking to specific subcellular sites.
An issue, that remained to be elucidated in more detail, is the mechanism of effector activation. Notably, identification of additional components of the RAS signal transduction is a critical step towards understanding the relationship between the RAS proteins and the selective activation of respective effectors. Functional reconstitution of RAS interaction networks by using appropriate liposomes and full-length effector proteins may eventually provide fundamental insights into the functional characterization of multiprotein complexes of RAS and the complete identification of regulatory mechanisms. Multiple amino acid sequence alignment of RAS proteins with high similarities has been determined by ClustalW. Interaction regions, R1 to R5, at interface with the RB and RA effector domains are illustrated by arrowhead (color-coding is the same as in Fig 4: R1 in red; R2 in green; R3 in blue; R4 in purple; R4 in orange). The secondary structure elements, the α helices and β sheets, of the G domain were deduced from the HRAS crystal structure (PDB code: 5P21) [119] . G1 to G5 boxes indicate the presence of five essential GDP/GTP binding (G) motifs. The three amino acid deviations between RAS and RRAS isoforms that are critical selectivity-determining residues for effector binding are highlighted in red. 
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